Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
INmune Bio Inc. will report its first quarter 2024 financial results and provide a corporate update on May 9. The clinical-stage immunology company is focused on developing treatments leveraging a patient's innate immune system to combat diseases. A conference call and webcast will be hosted at 4:30 PM ET on the same day.
INmune Bio Inc. provides an update on two patients from the Phase 1b Alzheimer’s Disease Trial who have been receiving XPro™ for over three years under the Australian compassionate use program. Both patients have shown stable cognitive function and a desire to continue treatment. The long-term administration of XPro™ has been safe and well-tolerated, according to primary care physicians.
INmune Bio Inc., a clinical-stage immunology company, has completed the first cohort and initiated the second cohort of a Phase 1/2 study of INKmune™ Natural Killer Cell Therapy for metastatic castration-resistant prostate cancer. The company is encouraged by the safety and efficacy of the therapy, with approval granted to proceed with the second dose level. Prof. Mark Lowdell Ph.D., CSO of INmune Bio, highlights the potential of INKmune to transform resting NK cells into cancer-killing cells, offering a promising therapy for prostate cancer patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.